Anupam Rama
Stock Analyst at JP Morgan
(4.47)
# 283
Out of 5,165 analysts
305
Total ratings
50.4%
Success rate
21.82%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $176 → $177 | $130.81 | +35.31% | 22 | Mar 12, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $120 → $74 | $21.79 | +239.61% | 4 | Mar 12, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Neutral | $27 → $22 | $21.34 | +0.75% | 6 | Mar 11, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $89 → $94 | $71.41 | +31.63% | 13 | Mar 10, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $33 → $45 | $23.96 | +87.81% | 12 | Mar 9, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $36 → $37 | $19.02 | +94.53% | 19 | Mar 5, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $32 | $14.16 | +126.07% | 1 | Mar 3, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $46 → $39 | $19.00 | +105.26% | 13 | Feb 5, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $40.35 | +137.92% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $35.75 | +87.41% | 9 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $40 | $14.20 | +181.69% | 2 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $147 → $145 | $100.06 | +44.91% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $10.15 | -40.89% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $20 | $12.23 | +63.53% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $32 | $16.10 | +98.76% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $12.71 | +33.75% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.38 | +32.17% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $7.60 | +44.74% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $24.00 | - | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $34.93 | +126.17% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $7.34 | +49.86% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $52.16 | -29.06% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.50 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $16.84 | +42.52% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $66.12 | +20.99% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $28.18 | +56.14% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $47.05 | -14.98% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.16 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.07 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.97 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.89 | +120.71% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $6.20 | +3,932.26% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.61 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $60.51 | -4.15% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $13.97 | -14.10% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $9.45 | +291.53% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $96.26 | -42.86% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.40 | +265.38% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $13.92 | +101.15% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $28.52 | +89.34% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.19 | +23,836.17% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.45 | +46.34% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $315.82 | -56.62% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $6.94 | +591.64% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.94 | +3,083.70% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $66.40 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.40 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
Mar 12, 2026
Maintains: Overweight
Price Target: $176 → $177
Current: $130.81
Upside: +35.31%
Ultragenyx Pharmaceutical
Mar 12, 2026
Maintains: Overweight
Price Target: $120 → $74
Current: $21.79
Upside: +239.61%
Day One Biopharmaceuticals
Mar 11, 2026
Downgrades: Neutral
Price Target: $27 → $22
Current: $21.34
Upside: +0.75%
BridgeBio Pharma
Mar 10, 2026
Maintains: Overweight
Price Target: $89 → $94
Current: $71.41
Upside: +31.63%
Syndax Pharmaceuticals
Mar 9, 2026
Maintains: Overweight
Price Target: $33 → $45
Current: $23.96
Upside: +87.81%
Apellis Pharmaceuticals
Mar 5, 2026
Maintains: Overweight
Price Target: $36 → $37
Current: $19.02
Upside: +94.53%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $14.16
Upside: +126.07%
Zai Lab
Feb 5, 2026
Maintains: Overweight
Price Target: $46 → $39
Current: $19.00
Upside: +105.26%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $40.35
Upside: +137.92%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $35.75
Upside: +87.41%
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $14.20
Upside: +181.69%
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $100.06
Upside: +44.91%
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $10.15
Upside: -40.89%
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $12.23
Upside: +63.53%
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $16.10
Upside: +98.76%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $12.71
Upside: +33.75%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.38
Upside: +32.17%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $7.60
Upside: +44.74%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $24.00
Upside: -
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $34.93
Upside: +126.17%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $7.34
Upside: +49.86%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $52.16
Upside: -29.06%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.50
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $16.84
Upside: +42.52%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $66.12
Upside: +20.99%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $28.18
Upside: +56.14%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $47.05
Upside: -14.98%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.16
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.07
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $7.97
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.89
Upside: +120.71%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $6.20
Upside: +3,932.26%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.61
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $60.51
Upside: -4.15%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $13.97
Upside: -14.10%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $9.45
Upside: +291.53%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $96.26
Upside: -42.86%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.40
Upside: +265.38%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $13.92
Upside: +101.15%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $28.52
Upside: +89.34%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.19
Upside: +23,836.17%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.45
Upside: +46.34%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $315.82
Upside: -56.62%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $6.94
Upside: +591.64%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.94
Upside: +3,083.70%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $66.40
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -